Hub Director named Queensland Young Tall Poppy of the Year
Hub Director A/Prof. Seth Cheetham has received the top honour in the 2026 Queensland Young Tall Poppy Science Awards, one of nine UQ researchers recognised this year for research and science communication.
Read more →
Australia's mRNA revolution is accelerating drug development
The Scientist reports on how local manufacturing capacity and a fast clinical trials pathway are shortening the road from mRNA design to first-in-human studies, with comment from Hub Director A/Prof. Seth Cheetham and PhD scholar Bettina Dietmair.
Read more →
Professor Brandon Wainwright AM appointed Director and CEO of QIMR Berghofer
Hub chief investigator Professor Brandon Wainwright AM has been appointed Director and CEO of QIMR Berghofer Medical Research Institute, commencing on 7 September 2026.
Read more →
Moderna cancer vaccine stops melanoma returning: what comes next for personalised treatments
Hub Director A/Prof. Seth Cheetham gave expert comment to Nature on Phase III results for intismeran, the Moderna and Merck personalised mRNA cancer vaccine that reduced the risk of melanoma returning.
Read more →
New melanoma vaccine reduces risk of cancer return and spread during trial
Hub Director A/Prof. Seth Cheetham appeared on 10 News to explain what the Phase III melanoma result means for patients at high risk of their cancer returning.
Read more →
Harnessing mRNA for more targeted cancer treatment
Tour de Cure funding supports two Hub researchers: Dr Liam O'Brien, engineering synthetic cytokines that act on tumours while sparing healthy tissue, and PhD scholar Hannah Tompkins, developing mRNA vaccines that make treatment-resistant cancer cells visible to the immune system.
Read more →
From discovery to the clinic: Seth Cheetham takes the helm at NBF
A/Prof. Seth Cheetham has been appointed Director of the National Biologics Facility, where he will help bridge the gap between university research discoveries and the clinical development of breakthrough medicines.
Read more →Australian trial of personalised vaccines to treat children with deadly brain cancers
A world-first clinical trial will test personalised mRNA vaccines for children with advanced brain tumours. PaedNEO-VAX is backed by a $2.578 million Australian Government investment and will run across 8 paediatric hospitals.
Read more →
From tadpoles to therapeutics: Laura's journey to AIBN
Dr Laura Leighton, a postdoctoral fellow at AIBN's BASE facility, applies a lifelong curiosity about biology to making mRNA medicines safer and more targeted.
Read more →
AIBN researchers secure nearly $5 million in ARC Fellowship funding
A/Prof. Seth Cheetham received a $1.13 million ARC Future Fellowship to develop ultra-stable cloaked mRNAs that could improve manufacturing efficiency and stability while reducing production costs.
Read more →
Getting personal in the fight against cancer
The University of Queensland established a laboratory dedicated to designing, manufacturing and delivering personalised mRNA cancer vaccines, addressing a critical gap in Australia's drug development infrastructure.
Read more →
How personalised mRNA vaccines could revolutionise cancer treatment
Hub Director A/Prof. Seth Cheetham presents at TEDxUQ on how custom-designed mRNA vaccine technology could change the way cancers are treated, patient by patient.
Read more →